Navigation Links
Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine

Summary: Follow-up RAS data presented at ASCO

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gave a presentation titled "RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicates that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of other proprietary cancer peptide vaccines, including GV1001 which is in phase III clinical trials.

Hørsholm, June 4, 2007

Jakob Schmidt Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepat itis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.

http://hugin.info/131680/R/1130841/211128.pdf


'"/>




Related medicine technology :

1. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
2. Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
8. Apollo develops needle-free topical vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):